Question 10 of 20 Fundamentals Concept
What does each phase of clinical development try to learn?
Short answer
Phase 1 studies human pharmacology: first safety, tolerability and how the body handles the drug. Phase 2 explores efficacy, dose and the right population. Phase 3 confirms safety and efficacy to support approval. Phase 4 covers studies after approval. ICH E8(R1) stresses that phases describe a program and are not a rule.
Why
ICH E8(R1) groups studies by objective rather than by number. Human pharmacology studies, usually called phase 1, protect participants first and estimate tolerability across doses, pharmacokinetics such as clearance and accumulation, and early pharmacodynamic activity. They may enroll healthy volunteers or patients.
In oncology, first in human studies are often in patients because the drugs are too toxic for healthy people. Exploratory studies, usually phase 2, test efficacy in a selected patient group and refine dose, regimen, population and endpoints. Confirmatory studies, usually phase 3, are designed to confirm that the drug is safe and effective for the intended use and often form the basis for approval.
Post approval studies, usually phase 4, answer questions not needed for approval, such as long term safety or comparison with standard care. The guideline says phases may overlap or be combined. A seamless phase 2 and 3 design, or a pharmacokinetic study in renal impairment run during phase 3, are normal.
So naming the objective of a study is more useful than naming its phase.
A strong answer covers
- Human pharmacology, exploratory, confirmatory and post approval objectives
- Phases describe a program, not a requirement
- Phases can overlap or be combined
- First in human studies in patients when drugs are too toxic for volunteers
- Phase 4 answers questions approval did not need
Common mistakes
- Saying phase 1 always uses healthy volunteers.
- Treating phases as strict gates that can never overlap.
- Assuming phase 3 is only about efficacy, when it also builds the safety database.
The interviewer might ask next
What would justify combining phase 2 and phase 3 into a single seamless trial?